MA32933B1 - Combinaison d'inhibiteurs de hspo90 et d'herceptine - Google Patents
Combinaison d'inhibiteurs de hspo90 et d'herceptineInfo
- Publication number
- MA32933B1 MA32933B1 MA33957A MA33957A MA32933B1 MA 32933 B1 MA32933 B1 MA 32933B1 MA 33957 A MA33957 A MA 33957A MA 33957 A MA33957 A MA 33957A MA 32933 B1 MA32933 B1 MA 32933B1
- Authority
- MA
- Morocco
- Prior art keywords
- combination
- hspo90
- herceptin
- inhibitors
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne une combinaison pharmaceutique comprenant un inhibiteur de Hsp90 et un inhibiteur de HER2, et des procédés d'utilisation de cette combinaison pour traiter des troubles prolifératifs.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08170255 | 2008-11-28 | ||
EP08170261 | 2008-11-28 | ||
PCT/EP2009/065861 WO2010060939A2 (fr) | 2008-11-28 | 2009-11-25 | Combinaison d'inhibiteurs de hsp90 et d'herceptine |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32933B1 true MA32933B1 (fr) | 2012-01-02 |
Family
ID=42226166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33957A MA32933B1 (fr) | 2008-11-28 | 2009-11-25 | Combinaison d'inhibiteurs de hspo90 et d'herceptine |
Country Status (17)
Country | Link |
---|---|
US (5) | US20110236379A1 (fr) |
EP (1) | EP2370103B1 (fr) |
JP (3) | JP2012510443A (fr) |
KR (3) | KR20110103980A (fr) |
CN (1) | CN102227227B (fr) |
AU (1) | AU2009319050B2 (fr) |
BR (1) | BRPI0922082A2 (fr) |
CA (1) | CA2742743C (fr) |
ES (1) | ES2573295T3 (fr) |
IL (1) | IL212736A0 (fr) |
MA (1) | MA32933B1 (fr) |
MX (1) | MX2011005671A (fr) |
RU (1) | RU2532375C2 (fr) |
TN (1) | TN2011000214A1 (fr) |
TW (1) | TW201024294A (fr) |
WO (1) | WO2010060939A2 (fr) |
ZA (1) | ZA201103228B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107108591B (zh) * | 2015-01-22 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 作为hsp90抑制剂的间苯二酚类衍生物 |
SG10201801219VA (en) | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
KR20230127880A (ko) | 2022-02-25 | 2023-09-01 | 중앙대학교 산학협력단 | 헤테로아릴 유도체를 유효성분으로 함유하는 her2 억제용 조성물 |
CN116789671A (zh) * | 2022-03-22 | 2023-09-22 | 上海维申医药有限公司 | 作为Toll样受体激动剂的嘧啶并哒嗪酮类化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
US20090197852A9 (en) * | 2001-08-06 | 2009-08-06 | Johnson Robert G Jr | Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor |
EA009919B1 (ru) * | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения изоксазола |
CN101287734B (zh) * | 2005-09-30 | 2011-07-20 | 诺华公司 | 2-氨基-7,8-二氢-6H-吡啶并[4,3-d]嘧啶-5-酮 |
JO2783B1 (en) * | 2005-09-30 | 2014-03-15 | نوفارتيس ايه جي | Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones |
-
2009
- 2009-11-25 CN CN200980147681.1A patent/CN102227227B/zh not_active Expired - Fee Related
- 2009-11-25 AU AU2009319050A patent/AU2009319050B2/en not_active Ceased
- 2009-11-25 MA MA33957A patent/MA32933B1/fr unknown
- 2009-11-25 KR KR1020117014763A patent/KR20110103980A/ko not_active Application Discontinuation
- 2009-11-25 BR BRPI0922082A patent/BRPI0922082A2/pt not_active IP Right Cessation
- 2009-11-25 EP EP09756754.9A patent/EP2370103B1/fr active Active
- 2009-11-25 US US13/131,298 patent/US20110236379A1/en not_active Abandoned
- 2009-11-25 MX MX2011005671A patent/MX2011005671A/es active IP Right Grant
- 2009-11-25 WO PCT/EP2009/065861 patent/WO2010060939A2/fr active Application Filing
- 2009-11-25 CA CA2742743A patent/CA2742743C/fr not_active Expired - Fee Related
- 2009-11-25 KR KR1020167019843A patent/KR101782576B1/ko active IP Right Grant
- 2009-11-25 RU RU2011126251/15A patent/RU2532375C2/ru not_active IP Right Cessation
- 2009-11-25 ES ES09756754.9T patent/ES2573295T3/es active Active
- 2009-11-25 JP JP2011537973A patent/JP2012510443A/ja active Pending
- 2009-11-25 KR KR1020177026696A patent/KR20170113683A/ko not_active Application Discontinuation
- 2009-11-27 TW TW098140690A patent/TW201024294A/zh unknown
-
2011
- 2011-05-03 TN TN2011000214A patent/TN2011000214A1/fr unknown
- 2011-05-03 ZA ZA2011/03228A patent/ZA201103228B/en unknown
- 2011-05-05 IL IL212736A patent/IL212736A0/en unknown
-
2012
- 2012-05-08 US US13/466,190 patent/US20120219550A1/en not_active Abandoned
-
2014
- 2014-05-21 US US14/284,240 patent/US20140328834A1/en not_active Abandoned
-
2015
- 2015-02-13 US US14/621,808 patent/US20150209362A1/en not_active Abandoned
- 2015-05-07 JP JP2015095092A patent/JP2015187116A/ja not_active Withdrawn
-
2016
- 2016-06-02 US US15/171,410 patent/US20160346292A1/en not_active Abandoned
-
2017
- 2017-04-06 JP JP2017075723A patent/JP2017141278A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TN2011000214A1 (en) | 2012-12-17 |
EP2370103B1 (fr) | 2016-03-23 |
WO2010060939A3 (fr) | 2010-10-07 |
KR101782576B1 (ko) | 2017-09-27 |
ES2573295T3 (es) | 2016-06-07 |
US20140328834A1 (en) | 2014-11-06 |
JP2017141278A (ja) | 2017-08-17 |
AU2009319050A1 (en) | 2010-06-03 |
US20160346292A1 (en) | 2016-12-01 |
JP2012510443A (ja) | 2012-05-10 |
RU2011126251A (ru) | 2013-01-10 |
BRPI0922082A2 (pt) | 2015-12-15 |
AU2009319050B2 (en) | 2014-01-30 |
KR20110103980A (ko) | 2011-09-21 |
RU2532375C2 (ru) | 2014-11-10 |
MX2011005671A (es) | 2011-06-20 |
EP2370103A2 (fr) | 2011-10-05 |
JP2015187116A (ja) | 2015-10-29 |
US20110236379A1 (en) | 2011-09-29 |
KR20170113683A (ko) | 2017-10-12 |
CN102227227B (zh) | 2014-05-28 |
CA2742743A1 (fr) | 2010-06-03 |
US20150209362A1 (en) | 2015-07-30 |
KR20160090911A (ko) | 2016-08-01 |
ZA201103228B (en) | 2012-03-28 |
WO2010060939A2 (fr) | 2010-06-03 |
CN102227227A (zh) | 2011-10-26 |
US20120219550A1 (en) | 2012-08-30 |
TW201024294A (en) | 2010-07-01 |
CA2742743C (fr) | 2017-05-23 |
IL212736A0 (en) | 2011-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32934B1 (fr) | Combinaisons inhibitrices hsp90 | |
IN2012DN03012A (fr) | ||
MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
MX2014000518A (es) | Inhibidores de la tirosina quinasa de bruton. | |
UA99284C2 (ru) | ИНГИБИТОРЫ р70 S6-КИНАЗЫ | |
IN2012DN03883A (fr) | ||
BR112015020466A2 (pt) | inibidores de cdc7 | |
EA201490161A1 (ru) | Соединения - ингибиторы сигналинга, опосредуемого рецептором notch | |
EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
EA201170872A1 (ru) | Ингибиторы протеинкиназы | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
WO2010071846A3 (fr) | Composés pour traiter des états neuropsychiatriques | |
SG179085A1 (en) | Pi3 kinase inhibitors and uses thereof | |
EA201070256A1 (ru) | Способ и промежуточные соединения для получения ингибиторов интегразы | |
GB2460597A (en) | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
EA201270590A1 (ru) | Ингибиторы акт | |
EA201171063A1 (ru) | Фармацевтические составы олмесартана | |
EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
EA201490268A1 (ru) | Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор | |
EA200970164A1 (ru) | Ингибиторы каспазы на основе пиридазинонового каркаса | |
MA32933B1 (fr) | Combinaison d'inhibiteurs de hspo90 et d'herceptine | |
WO2010148177A3 (fr) | Composés, compositions, procédés de synthèse et procédés de traitement |